Home › Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia clinical trials recruiting in the U.S.
137 studies for Acute Lymphoblastic Leukemia are recruiting participants at sites across the United States.
Cities with the most studies
- Houston, TX28 studies
- New York City, NY22 studies
- Seattle, WA22 studies
- Baldwin Park, CA21 studies
- Atlanta, GA20 studies
- Chicago, IL20 studies
- Memphis, TN17 studies
- Philadelphia, PA16 studies
- Washington, DC16 studies
- Los Angeles, CA15 studies
- Boston, MA15 studies
- Mountain View, CA14 studies
- Durham, NC13 studies
- Cincinnati, OH13 studies
- Minneapolis, MN12 studies
- Columbus, OH11 studies
- Tampa, FL10 studies
- Salt Lake City, UT10 studies
- Portland, OR9 studies
- Aurora, CO9 studies
- Charlotte, NC9 studies
- Baltimore, MD9 studies
- Edison, NJ9 studies
- Nashville, TN8 studies
- San Antonio, TX8 studies
- Cleveland, OH8 studies
- Miami, FL8 studies
- St. Louis, MO7 studies
- Birmingham, AL7 studies
- Denver, CO7 studies
- Phoenix, AZ6 studies
- San Diego, CA6 studies
- Detroit, MI6 studies
- Milwaukee, WI6 studies
- Queens, NY6 studies
- Oklahoma City, OK6 studies
- Pittsburgh, PA6 studies
- Cedar Rapids, IA5 studies
- The Bronx, NY5 studies
- Indianapolis, IN5 studies
By state
- Alabama7 studies
- Arizona7 studies
- Arkansas5 studies
- California41 studies
- Colorado13 studies
- Connecticut4 studies
- District of Columbia10 studies
- Florida19 studies
- Georgia21 studies
- Hawaii3 studies
- Illinois21 studies
- Indiana6 studies
- Iowa5 studies
- Kansas5 studies
- Kentucky4 studies
- Louisiana6 studies
- Maine3 studies
- Maryland16 studies
- Massachusetts15 studies
- Michigan8 studies
- Minnesota14 studies
- Mississippi3 studies
- Missouri7 studies
- Nebraska4 studies
- Nevada3 studies
- New Jersey11 studies
- New Mexico3 studies
- New York30 studies
- North Carolina22 studies
- Ohio23 studies
- Oklahoma8 studies
- Oregon10 studies
- Pennsylvania21 studies
- Rhode Island3 studies
- South Carolina5 studies
- South Dakota3 studies
- Tennessee23 studies
- Texas30 studies
- Utah10 studies
- Virginia9 studies
- Washington23 studies
- West Virginia4 studies
- Wisconsin9 studies
Recently updated studies
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Nov 13, 2026 · NCT07109219A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
RecruitingPhase 1
Ages 0 to 18 · All sexes · Updated Nov 13, 2026 · NCT06173518A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...
Recruiting
Ages 1 to 25 · All sexes · Updated Nov 13, 2026 · NCT05621291Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Nov 13, 2026 · NCT07572136TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
RecruitingPhase 1/2
Up to age 1 · All sexes · Updated Nov 12, 2026 · NCT05848687Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT06308588Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT03263572HPC Offered for PRESERVE Expansion
RecruitingObservational study
Ages 12 to 80 · All sexes · Updated Nov 6, 2026 · NCT07145411Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Nov 4, 2026 · NCT05334069Auto Stem Cell Transplant for Lymphoma Patients
RecruitingPhase 2
Up to age 75 · All sexes · Updated Nov 4, 2026 · NCT03125642Feasibility and Acceptability of Remote Saliva Collection
RecruitingObservational studyHealthy volunteers welcome
Ages 8 to 18 · All sexes · Updated Nov 3, 2026 · NCT07884474Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
RecruitingPhase 1
Ages 3 to 35 · All sexes · Updated Nov 3, 2026 · NCT02390752Personalized NK Cell Therapy in CBT
RecruitingPhase 2
Ages 15 to 80 · All sexes · Updated Nov 2, 2026 · NCT02727803Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Nov 2, 2026 · NCT06904066Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
RecruitingPhase 1/2Healthy volunteers welcome
Up to age 50 · All sexes · Updated Oct 30, 2026 · NCT05322850225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
RecruitingPhase 1
Ages 18 to 70 · All sexes · Updated Oct 30, 2026 · NCT06287944A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL)
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT07614022Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RecruitingObservational study
Ages 0 to 38 · All sexes · Updated Oct 29, 2026 · NCT06131801Prophylactic DLI-X for Leukemia Relapse After HCT
RecruitingPhase 1
Up to age 65 · All sexes · Updated Oct 29, 2026 · NCT07254793Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Oct 28, 2026 · NCT01137643Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RecruitingPhase 1
7 Months – 21 Years · All sexes · Updated Oct 27, 2026 · NCT02508038Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
RecruitingPhase 2
6 Months – 65 Years · All sexes · Updated Oct 26, 2026 · NCT06013423CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
RecruitingPhase 1/2
Ages 3 to 39 · All sexes · Updated Oct 26, 2026 · NCT05442515CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
RecruitingPhase 2
Ages 3 to 65 · All sexes · Updated Oct 26, 2026 · NCT07328503CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
RecruitingPhase 2Healthy volunteers welcome
Ages 18 to 75 · All sexes · Updated Oct 23, 2026 · NCT06059391From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.